Mostrando 10 resultados de: 21
Filtros aplicados
Publisher
Clinical Pharmacology and Therapeutics(3)
European Journal of Clinical Pharmacology(2)
Acta Psychiatrica Scandinavica(1)
Anales de Medicina Interna(1)
Annals of Medicine(1)
Área temáticas
Farmacología y terapéutica(17)
Enfermedades(13)
Bioquímica(5)
Fisiología humana(5)
Medicina y salud(2)
Use of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity
ArticleAbstract: Thioridazine is metabolized in humans by CYP2D6 to mesoridazine, which is an active metabolite. TwoPalabras claves:CYP2D6, High-pressure liquid chromatography, pharmacogenetics, Therapeutic drug monitoring (TDM), ThioridazineAutores:Adrián LLerena, Benitez Rodriguez J., Berecz R., De la Rubia A., Norberto M.Fuentes:scopusAssessment of the debrisoquin and dextromethorphan phenotyping tests by gaussian mixture distributions analysis
ArticleAbstract: From a sample of 149 unrelated Spaniards, individuals were phenotyped for their ability to hydroxylaPalabras claves:Autores:Adrián LLerena, Avram M., Benitez Rodriguez J., C. Martinez, Cobaleda J., Gibbons R., Henthorn T., Krejcie T., Martinez C.Fuentes:scopusDEBRISOQUINE HYDROXYLATION PHENOTYPES IN HEALTHY VOLUNTEERS
OtherAbstract:Palabras claves:Autores:Adrián LLerena, Benitez Rodriguez J., Cobaleda J.Fuentes:scopusDebrisoquin oxidation polymorphism in a Spanish population
ArticleAbstract: The capacity for debrisoquin metabolism was determined in 377 healthy Spanish volunteers by measurinPalabras claves:Autores:Adrián LLerena, Benitez Rodriguez J., Cobaleda J.Fuentes:scopusDebrisoquine oxidation in schizophrenic patients treated with neuroleptics
ArticleAbstract:Palabras claves:debrisoquine, Neuroleptics, OXIDATION, SchizophreniaAutores:Adrián LLerena, Benitez Rodriguez J., Buemi A.L., Caputi A.P., Cobaleda J., García M.A., M. A. García, Piña B., Spina E.Fuentes:scopusDebrisoquine oxidation phenotype in psychiatric patients.
ArticleAbstract:Palabras claves:Autores:Adrián LLerena, Benitez Rodriguez J., Cobaleda J., García M.A., M. A. García, Martínez C., Piñas B.Fuentes:scopusAcetylator polymorphism in Parkinson's disease
ArticleAbstract: Acetylator phenotype has been determined using sulphamethazine in 100 patients with Parkinson's disePalabras claves:acetylator phenotype, debrisoquine oxidation, drug polymorphism, Parkinsonism, sulphamethazineAutores:Adrián LLerena, Benitez Rodriguez J., C. Martinez, Cobaleda J., F. J. Jimenez, Fernandez-Gundin M.J., Jimenez F.J., Ladero J.M., Martinez C., Muñoz J.J.Fuentes:scopusInteraction between prajmaline and metoprotol: a possible pharmacogenetic explanation
OtherAbstract:Palabras claves:Autores:Adrián LLerena, Benitez Rodriguez J., Berecz R.Fuentes:scopusInterethnic differences in drug metabolism: Influence of genetic and environmental factors on debrisoquine hydroxylation phenotype
Conference ObjectAbstract: Genetic and environmental factors are determinants of the interindividual and interethnic variabilitPalabras claves:CYP2D6, debrisoquine, gender, pharmacogenetics, smokingAutores:Adrián LLerena, Benitez Rodriguez J., Cobaleda J., Martínez C.Fuentes:scopusClozapine disposition covaries with CYP1A2 activity determined by a caffeine test.
ArticleAbstract: In a previous study we showed that the disposition of clozapine after a single oral dose is unrelatePalabras claves:Autores:Adrián LLerena, Alm C., Benitez Rodriguez J., Bertilsson L., Bondesson U., Carrillo J., Dahl M.L., Lindstrom L., Ramos S., Rodriguez de la Rubia I.Fuentes:scopus